This content is available for reuse with permission. If you are interested in reusing this content, please email newsroom@davita.com.
As DaVita expands access to Expanded hemodialysis (HD), some patients who have recently started the treatment have shared positive personal experiences, including changes in how they feel day to day. These individual stories reflect patients’ perspectives and experiences and should not be interpreted as evidence of clinical outcomes for all patients. Real-World Patient Experiences The […]
DaVita will also continue hemodiafiltration (HDF) pilots to advance a comprehensive approach to middle molecule clearance. In the ongoing pursuit of improved outcomes in kidney care, few targets have been as stubborn as the middle molecule gap. When middle molecules — larger uremic toxins that are not effectively cleared during standard high-flux dialysis — accumulate, […]
New data from the MOTheR trial1, one of the most rigorous head-to-head studies of advanced dialysis therapies to date, marks an important step forward in how the kidney care community approaches treatment for patients with end stage kidney disease. Presented at the European Renal Association (ERA) Congress in June 2026, the prospective randomized controlled trial […]
As artificial intelligence (AI) continues to take hold across all industries, Adam Weinstein, MD, chief medical information officer for DaVita, highlights how new technological capabilities also help make the human connection more central to healthcare. Recently, a New York Times article explored the question of whether advancements to AI in medicine could reduce the value […]
For approximately 80,000 Americans, home dialysis offers a sense of normalcy and stability amid many changes that inevitably come with a diagnosis of kidney failure. Home dialysis includes both peritoneal dialysis (PD) and home hemodialysis (HHD), differentiated options that allow patients to complete treatments with greater schedule flexibility. This not only provides a greater sense […]